Expertise in
26
conditions

Dr. Herschel Wallen

Hematology | Oncology
Samaritan Hematology & Oncology-Corvallis
441 NW Elks Dr Ste 100, 
Corvallis, OR 
Accepting New Patients
Offers Telehealth
Expertise in
26
conditions
Samaritan Hematology & Oncology-Corvallis
441 NW Elks Dr Ste 100, 
Corvallis, OR 

Overview

Herschel Wallen is a Hematologist and an Oncologist practicing medicine in Corvallis, Oregon.

Dr. Wallen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 9 clinical trials. Dr. Wallen is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

Samaritan Lebanon Community Hospital
Samaritan Pacific Community Hospital
Samaritan Albany General Hospital
Good Samaritan Regional Medical Center
Salem Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Samaritan Hematology & Oncology-Corvallis
441 NW Elks Dr Ste 100, Corvallis, OR 97330
Other Locations
Good Samaritan Regional Medical Center Hematology And Oncology
441 Nw Elks Dr, Ste 100, Corvallis, OR 97330

Additional Areas of Focus

Dr. Wallen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: MEDI0562
Study Phase: Phase 1
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Bicalutamide
Study Phase: Phase 2
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: MK-3475, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug, Dietary supplement
Study Drugs: Cyclophosphamide, Indomethacin, Omeprazole
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab
Study Phase: Phase 1
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

1 Total Publications

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Journal: BMC cancer
Published: January 23, 2018
Similar Doctors
Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Willamette Valley Cancer Institute And Research Center

520 Country Club Pkwy, 
Eugene, OR 
 (38.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeff Sharman is an Oncologist practicing medicine in Eugene, Oregon. Dr. Sharman is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Diffuse Large B-Cell Lymphoma (DLBCL), and Small Lymphocytic Lymphoma (SLL). Dr. Sharman is currently accepting new patients.

Expertise in
38
conditions
Dr. Christopher Yasenchak
Hematology | Oncology
Expertise in
38
conditions
Dr. Christopher Yasenchak
Hematology | Oncology
Referral may be required

Oncology Associates Of Oregon P C.

520 Country Club Pkwy, 
Eugene, OR 
 (38.0 miles away)
541-683-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Yasenchak is a Hematologist and an Oncologist practicing medicine in Eugene, Oregon. Dr. Yasenchak is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Classical Hodgkin Lymphoma, and Multiple Myeloma. Dr. Yasenchak is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Corvallis Clinic PC

444 NW Elks Dr, 
Corvallis, OR 
 (0.1 miles away)
541-754-1256
Languages Spoken:
English, Cantonese, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathleen Yang is an Oncologist practicing medicine in Corvallis, Oregon. Dr. Yang is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Cervical Cancer, Bladder Reconstruction, and Hernia Surgery. Dr. Yang is currently accepting new patients.

Frequently Asked Questions about Dr. Herschel Wallen

How do I make an appointment with Dr. Herschel Wallen?

You can book an appointment with Dr. Herschel Wallen by calling their office at 541-768-4950. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Herschel Wallen a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Herschel Wallen is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Herschel Wallen specialize in?

While Dr. Herschel Wallen is a Hematology, they have specific expertise in Thrombocytopenia, Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Herschel Wallen participate in research or clinical trials?

Yes. Dr. Herschel Wallen has published 1 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Herschel Wallen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Herschel Wallen accept my insurance?

Dr. Herschel Wallen accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 541-768-4950 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wallen's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile